Elironrasib clinical trials
Also written RMC-6291.
How each study uses elironrasib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the elironrasib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test elironrasib.
- Mar 2027Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsPhase 1 · Revolution Medicines, Inc.
- Jun 2027Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCPhase 1/2 · Revolution Medicines, Inc.
Studies
Open first, then newest update. How each study uses elironrasib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCRecruitingPhase 1/2Revolution Medicines, Inc.NCT06162221Written as RMC-6291
- Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT06128551Written as Elironrasib
- Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsActive, not recruitingPhase 1Revolution Medicines, Inc.NCT05462717Written as RMC-6291
Given beside what is tested · 1 — elironrasib is usual care or a partner of the new treatment
Codes
What other systems call elironrasib · ClinicalTrials.gg INT015781
- UNII (FDA) 942KVV5CJPELIRONRASIBConfirmed FDA, Wikidata
- Wikidata Q140529143elironrasibConfirmed FDA, Wikidata
- NCI Thesaurus C189824ElironrasibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 942KVV5CJP | ELIRONRASIB | Confirmed FDA, Wikidata |
| Wikidata | Q140529143 | elironrasib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C189824 | Elironrasib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.